U.S. Healthcare Cold Chain Packaging Market To Reach $9.32 Billion By 2033

U.S. Healthcare Cold Chain Packaging Market Growth & Trends

The U.S. healthcare cold chain packaging market size is anticipated to reach USD 9.32 billion by 2033 and is anticipated to expand at a CAGR of 12.2% from 2026 to 2033, according to a new report by Grand View Research, Inc. Rising production and distribution of temperature-sensitive biologics, vaccines, and cell & gene therapies in the U.S. is driving sustained demand for compliant cold chain packaging solutions.

The rapid expansion of biopharmaceutical manufacturing in the U.S. is a core growth driver for the healthcare cold chain packaging industry. The country continues to attract significant investment from global biologics companies seeking proximity to advanced research ecosystems, skilled labor, and a predictable regulatory environment. This trend is reinforced by strategic acquisitions and capacity additions, such as Samsung Biologics’ December 2025 acquisition of Human Genome Sciences’ manufacturing facility in Rockville, Maryland. The transaction provided Samsung with an immediate 60,000-liter drug substance capacity and established its first U.S. manufacturing footprint, increasing demand for validated cold chain packaging solutions to support internal logistics and outbound distribution of temperature-sensitive biologics.

Vaccine manufacturing expansion further strengthens demand for reliable cold chain packaging across the U.S. healthcare supply chain. In March 2025, Merck commissioned a USD 1 billion vaccine manufacturing facility at its Durham, North Carolina campus with the capability to produce more than 70 million doses annually, including Gardasil and other routine and pediatric vaccines. High-volume vaccine output at this scale requires consistent temperature control from production and storage through nationwide distribution. As a result, pharmaceutical companies are increasingly adopting standardized, high-performance cold chain packaging systems that support rapid throughput, regulatory compliance, and large-scale immunization programs.

The increasing complexity of biologics portfolios is also reshaping cold chain packaging requirements. Oncology therapies, cell and gene therapies, and advanced biologics frequently require ultra-low or cryogenic temperature conditions and involve smaller, high-value shipment volumes. The October 2025 opening of SciSafe’s biorepository facility in East Brunswick, New Jersey, which added more than 5 million cubic feet of GMP-compliant cryogenic and ultra-low temperature storage, highlights the expansion of specialized cold chain infrastructure in the U.S. This growth directly increases demand for advanced packaging solutions capable of maintaining extreme temperature ranges while ensuring traceability and chain of custody.

Furthermore, rising biopharmaceutical and vaccine production is increasing supply chain risk exposure and elevating quality expectations. Temperature excursions can result in significant financial losses and regulatory noncompliance, prompting manufacturers to prioritize robust cold chain packaging solutions. This environment is accelerating the adoption of high-performance insulated shippers, reusable pallet systems, and packaging integrated with monitoring and compliance validation. As domestic production capacity continues to expand, cold chain packaging is becoming a critical enabler of operational reliability and regulatory assurance in the U.S. healthcare market.

 Request a free sample copy or view report summary: U.S. Healthcare Cold Chain Packaging Market Report

U.S. Healthcare Cold Chain Packaging Market Report Highlights

• Based on product, insulated containers dominated the market with the largest revenue share of 40.1% in 2025. This is attributed to their widespread use across pharmaceuticals, biologics, and vaccines, offering reliable temperature control across diverse distribution routes. Their cost-effectiveness, reusability, and compatibility with both passive and active systems drove higher adoption by U.S. healthcare logistics providers.

• Based on packaging format, the passive segment dominated the market by recording the largest market share of 59.8% in 2025. This dominance is due to its lower total cost, operational simplicity, and wide suitability for U.S. domestic pharma and biologics distribution. Strong validation history, ease of regulatory compliance, and growing use in last-mile and direct-to-patient shipments supported higher adoption.

• Refrigerated (2°C-8°C) dominated the temperature requirement segment of the market and accounted for the largest revenue share of 41.9% in 2025. This outlook is due to the high volume of vaccines, insulin, monoclonal antibodies, and biologics distributed within this temperature range. Established cold chain infrastructure and standardized regulatory compliance for 2°C–8°C products in the U.S. further supported higher revenue contribution.

• The biopharmaceutical companies dominated the application segment by recording the largest market share of 37.7% in 2025. This dominance is due to its lower total cost, operational simplicity, and wide suitability for U.S. domestic pharma and biologics distribution. Strong validation history, ease of regulatory compliance, and growing use in last-mile and direct-to-patient shipments supported higher adoption.

• The U.S. market is moderately concentrated and dynamic, with established global leaders and niche players competing mainly on technological innovation, regulatory compliance, and service reliability rather than price.

U.S. Healthcare Cold Chain Packaging Market Segmentation

Grand View Research has segmented the U.S. healthcare cold chain packaging market based on product, temperature requirement, packaging format, and application:

U.S. Healthcare Cold Chain Packaging Product Outlook (Revenue, USD Million, 2021 - 2033)

• Insulated Pallet Shippers

• Insulated Containers

• Vacuum Insulated Panels

• Cold Packs & Refrigerants

• Labels & Sensors

• Others

U.S. Healthcare Cold Chain Packaging Temperature Requirement Outlook (Revenue, USD Million, 2021 - 2033)

• Controlled Room Temperature (CRT)

• Refrigerated (2°C-8°C)

• Frozen (-20°C to -40°C)

• Cryogenic (<-80°C)

U.S. Healthcare Cold Chain Packaging Format Outlook (Revenue, USD Million, 2021 - 2033)

• Active

• Passive

U.S. Healthcare Cold Chain Packaging Application Outlook (Revenue, USD Million, 2021 - 2033)

• Biopharmaceutical Companies

• Clinical Research Organizations

• Hospitals and Healthcare Providers

• Research Institutes & Labs

• Logistics and Distribution Companies

• Others

List of Key Players in the U.S. Healthcare Cold Chain Packaging Market 

• ThermoSafe Technologies Inc.

• Cryoport Systems, LLC

• Sealed Air Corporation

• Peli BioThermal LLC

• CSafe

• DGP Intelsius LLC